Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,685 stopped studies mapped to Malignant Thoracic Neoplasm and descendants · 90% state a reason
Over the 1,685 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05256381 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety… | Phase 2 | terminated | Feb 25, 2022 | SOTIO Biotech AG | Due to lack of expected efficacy shown at the time of the interim analysis | Efficacy / futility |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04504916 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors… | Phase 2 | terminated | Aug 7, 2020 | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Business reasons | Sponsor / business decision |
| NCT05194735 | Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects… | Phase 1 / Phase 2 | terminated | Jan 18, 2022 | Alaunos Therapeutics | Funding | Funding |
| NCT05609331 | Feasibility, Safety, and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy… | N/A | terminated | Nov 8, 2022 | M.D. Anderson Cancer Center | \<75 % participation | Other (stated, no rule matched) |
| NCT04373369 | Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer | Phase 2 | terminated | May 4, 2020 | Washington University School of Medicine | Insufficient Funding/Staff | Funding |
| NCT04982224 | Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With… | Phase 1 | terminated | Jul 29, 2021 | Regeneron Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT04964960 | Pembro+Chemo in Brain Mets | Phase 2 | terminated | Jul 16, 2021 | John L. Villano, MD, PhD | Slow Accrual | Enrollment / accrual |
| NCT04524689 | Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab…(CARMEN-LC05) | Phase 2 | terminated | Aug 24, 2020 | Sanofi | Sponsor decision, the decision is not related to any safety concern. | Safety / toxicity |
| NCT05469178 | A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated… | Phase 1 / Phase 2 | terminated | Jul 21, 2022 | BerGenBio ASA | Lack of efficacy | Efficacy / futility |
| NCT05513703 | A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in… | Phase 2 | terminated | Aug 24, 2022 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04543188 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and… | Phase 1 | terminated | Sep 10, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07284890.… | Safety / toxicity |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in… | Phase 1 | terminated | Feb 17, 2020 | Incyte Corporation | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT04926831 | Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC(Geometry-N) | Phase 2 | terminated | Jun 15, 2021 | Novartis Pharmaceuticals | The study was terminated early due to recruitment challenges. | Enrollment / accrual |
| NCT03392064 | A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects… | Phase 1 | suspended | Jan 5, 2018 | Amgen | Study on enrollment hold, may potentially resume. No active subjects on trial. | Enrollment / accrual |
| NCT05215951 | Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC(MINOVA) | Phase 2 | terminated | Jan 31, 2022 | AstraZeneca | Enrollment delay study timeline seriously. | Enrollment / accrual |
| NCT02549638 | Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell… | — | terminated | Sep 15, 2015 | Mayo Clinic | Lack of funding, slow accrual | Enrollment / accrual |
| NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Phase 1 | terminated | Jul 29, 2021 | Taiho Oncology, Inc. | After careful review of Taiho's ongoing portfolio and data obtained so far in the context of… | Safety / toxicity |
| NCT05317078 | A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin… | Phase 1 | terminated | Apr 7, 2022 | Amgen | Sponsor strategic decision | Sponsor / business decision |
| NCT04914897 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of… | Phase 2 | terminated | Jun 7, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04000529 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected… | Phase 1 | terminated | Jun 27, 2019 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT06264921 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | terminated | Feb 20, 2024 | NiKang Therapeutics, Inc. | This study was terminated as a result of Sponsor portfolio reprioritization. | Sponsor / business decision |
| NCT04619433 | A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects… | Phase 3 | terminated | Nov 6, 2020 | Jiangsu HengRui Medicine Co., Ltd. | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT02863055 | Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma(NEMO) | Phase 2 | terminated | Aug 11, 2016 | European Organisation for Research and Treatment of Cancer - EORTC | lack of scientific relevance (change in the treatment landscape) and poor recruitment | Enrollment / accrual |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Phase 1 | terminated | Feb 21, 2024 | Ikena Oncology | Limited resources and strategic priorities | Sponsor / business decision |
| NCT05556525 | Needle-Based Confocal Laser Endomicroscopy for Diagnosis of Lung Cancer in Patients With… | N/A | terminated | Sep 27, 2022 | Mayo Clinic | Slow accrual | Enrollment / accrual |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT03307759 | Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade…(SABRseq) | Phase 1 | terminated | Oct 12, 2017 | Peter MacCallum Cancer Centre, Australia | Slow patient accrual | Enrollment / accrual |
| NCT05472623 | Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab(Neo-Kan) | Phase 2 | withdrawn | Jul 25, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | no participants enrolled across sites | Enrollment / accrual |
| NCT06746324 | Assessing AI for Detecting Lung Nodules and Cancer: Pre- and Post-Deployment Study(AI-Lung) | — | withdrawn | Dec 24, 2024 | University of Florida | No IRB approval | Other (stated, no rule matched) |
| NCT00210171 | Concomitant Chemo-radiotherapy in Locally Advanced Non Small Cell Lung Cancer(BIB 01) | Phase 2 | withdrawn | Sep 21, 2005 | Institut Bergonié | The study was withdrawn due to logistic issues. | Other (stated, no rule matched) |
| NCT05662670 | A Phase I/II Study of WJ13404 Monotherapy in Patients With Advanced or Mentastatic… | Phase 1 / Phase 2 | terminated | Dec 22, 2022 | Suzhou Junjing BioSciences Co., Ltd. | Due to the adjustment of the R\&D strategy, Suzhou Junjing Biosciences Co., Ltd. decided to… | Sponsor / business decision |
| NCT04162678 | Fluid Biopsy for the Diagnosis of Lung Cancer | — | terminated | Nov 14, 2019 | University of Southern California | insufficient accrual | Enrollment / accrual |
| NCT06016270 | A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive… | Phase 1 / Phase 2 | terminated | Aug 29, 2023 | STCube, Inc. | Company strategy | Sponsor / business decision |
| NCT05577715 | A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell… | Phase 2 | terminated | Oct 13, 2022 | Bristol-Myers Squibb | Business objectives have changed | Sponsor / business decision |
| NCT06084689 | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures(EMPIRE) | Phase 2 | withdrawn | Oct 16, 2023 | Institut Bergonié | Discontinuation of molecule development | Other (stated, no rule matched) |
| NCT05245071 | Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5…(CARMEN-LC06) | Phase 2 | terminated | Feb 17, 2022 | Sanofi | Sponsor decision, the decision is not related to any safety concern. | Safety / toxicity |
| NCT06555263 | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic… | Phase 2 | withdrawn | Aug 15, 2024 | Sutro Biopharma, Inc. | Terminated Early | Other (stated, no rule matched) |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and… | Phase 1 | terminated | Aug 14, 2025 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04581824 | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus… | Phase 2 | terminated | Oct 9, 2020 | GlaxoSmithKline | Trial terminated by GSK for strategic reasons, after all participants completed treatment. This… | Safety / toxicity |
| NCT06676917 | Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With…(TUXEDO-5) | Phase 2 | withdrawn | Nov 6, 2024 | MedSIR | The clinical trial has not been approved by the regulatory authority. | Other (stated, no rule matched) |
| NCT07038915 | STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by… | Phase 2 | withdrawn | Jun 26, 2025 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT04773275 | A Clinical Evaluation of the Aliya™ System in Late Stage Cancer(INCITE LS) | N/A | terminated | Feb 26, 2021 | Galvanize Therapeutics, Inc. | Lack of enrollment | Enrollment / accrual |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 2, 2018 | MacroGenics | Business decision | Sponsor / business decision |
| NCT05124743 | HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T… | — | terminated | Nov 18, 2021 | Alaunos Therapeutics | TCR001-002 protocol was combined with TCR001-201 protocol, which was terminated due to business… | Sponsor / business decision |
| NCT05420636 | Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary… | Phase 2 | terminated | Jun 15, 2022 | Fox Chase Cancer Center | Closed to accrual due to low probability of successful outcomes | Enrollment / accrual |
| NCT05617313 | Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell… | Phase 2 | terminated | Nov 15, 2022 | Jeffrey Clarke | Study did not meet the criteria for continuation after interim analysis | Efficacy / futility |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | Phase 2 | terminated | Mar 5, 2019 | Washington University School of Medicine | Insufficient funding/staff | Funding |
| NCT05691829 | Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV…(IRRADIATE-Lung) | Phase 2 | terminated | Jan 20, 2023 | NYU Langone Health | Terminated due to insufficient enrollment. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 17, 2025source: clinicaltrials